Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) profit net of tax attributable to owners of the parent was up 8% year over year to 146.1 million yuan in the third quarter of the year from 135.7 million yuan, according to a filing with the Singapore Exchange on Wednesday.
Earnings per share came in at 0.19 yuan compared with 0.17 yuan in the year-ago period.
Revenue was down 3% year over year to 1.65 billion yuan from 1.70 billion yuan, mainly due to a decrease in commercial sales.
Shares of the pharmaceutical company were down nearly 2% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。